RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor

Bryce et al., NCT04470544, RECOVER, NCT04470544

Sep 2022

Source PDF All Studies Meta AnalysisMeta

RCT 100 patients showing no significant difference with camostat. Results are currently unclear - different mortality numbers are provided for all-cause mortality and mortality rate. The main outcome measures appear to be different due to only including "patients that submitted day 28 outcome data".

6 camostat RCTs have results missing long after expected1-6
The trials report a total of 1,092 patients, with 4 trials having actual enrollment of 578, and the remainder estimated.

Important missing comments or errors? Let us know.

1. Bryce et al., RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor, NCT04470544, clinicaltrials.gov/study/NCT04470544.clinicaltrials.gov.

2. Jeon et al., A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients, NCT04713176, clinicaltrials.gov/study/NCT04713176.clinicaltrials.gov.

3. Boutboul et al., A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID), NCT04608266, clinicaltrials.gov/study/NCT04608266.clinicaltrials.gov.

4. Keitel-Anselmino et al., Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals, NCT04681430, clinicaltrials.gov/study/NCT04681430.clinicaltrials.gov.

5. Palazuelos et al., Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients, NCT04530617, clinicaltrials.gov/study/NCT04530617.clinicaltrials.gov.

6. Levi et al., Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus (COSTA), NCT04355052, clinicaltrials.gov/study/NCT04355052.clinicaltrials.gov.

Bryce et al., 15 Sep 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, trial NCT04470544 (history) (RECOVER). Contact: Nguyen.Vy@mayo.edu, ClinicalResearch@tmcaz.com, Vimoktayon.Torsak@mayo.edu, Pecenka.Stacey@mayo.edu.

This Paper Camostat All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0